SEC Filing Analysis: Edwards Lifesciences Corp (EW)

Executive Summary

• Trading Significance: Low
• Key Takeaway: An officer received a routine grant of 1,160 restricted stock units as part of a standard compensation plan.
• Market Impact: Negligible. This is a non-market transaction with no immediate financial value and represents a tiny fraction of shares outstanding.

Company Information

Field	Value
Company	Edwards Lifesciences Corp
Ticker Symbol	EW
CIK	0001099800
Industry	Orthopedic, Prosthetic & Surgical Appliances & Supplies

Insider Information

Field	Value
Name	Dahl Andrew M.
CIK	0002022347
Title/Position	SVP, Corporate Controller
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-13
Transaction Code	A (Grant)
Security Type	Common Stock
Shares Involved	1160
Price Per Share	$0.00
Total Value	$0
Shares Owned After	9183.074
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.00%
Shares Transacted	1,160
% of Shares Outstanding	0.0002%
Post-Transaction Ownership	9,183 shares (0.0016% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction value is $0 and the number of shares is immaterial against the company's $48.79 billion market capitalization.
• Dilution Impact: The grant of 1,160 shares represents a negligible 0.0002% of the total shares outstanding, posing no meaningful dilution risk to existing shareholders.
• Transaction Significance: This is a standard compensatory award with no market signal. The shares vest over a four-year period, aligning the executive's interests with long-term shareholder value.

Additional Context

Transaction Notes

• Special Circumstances: The filing footnote confirms these are restricted stock units (RSUs) granted under the company's Long-Term Stock Incentive Compensation Program. They vest in four equal annual installments starting one year from the grant date.